Novo Nordisk's Great Hope Semaglutide Shines In Ph II Obesity Study

 
• By Alexandra Shimmings

Highly positive top-line weight loss results for Novo Nordisk's new GLP-1 agonist semaglutide are propelling it into Phase III trials next year for the notoriously tricky indication. The product is currently under review for type 2 diabetes.

Apples
• Source: Shutterstock

More from Clinical Trials

More from R&D